An adherent drug depot for retinal ganglion cell protection and regeneration in rat traumatic optic neuropathy models. Issue 37 (28th June 2021)

• Record Type: Journal Article
• Authors: Li, Lingli; Deng, Fen; Qiu, Haijun; Li, Yao; Gong, Zan; Wang, Lei; Wang, Jingjie; Wu, Wencan; Nan, Kaihui
• Is Part Of: RSC advances. Volume 11:Issue 37(2021)
• Page Start: 22761
• Page End: 22772
• Publication Date: 2021-06-28
• Subjects: Chemistry -- Periodicals; 540.5
• DOI: 10.1039/d0ra10362d
• Languages: English
• ISSNs: 2046-2069

Abstract

Abstract : Traumatic optic neuropathy (TON) describes an injury to the optic nerve following either blunt or penetrating trauma, and remains an important cause of vision loss. Abstract : Traumatic optic neuropathy (TON) describes an injury to the optic nerve following either blunt or penetrating trauma, and remains an important cause of vision loss. No generalized treatment of TON has been established so far to restore the injured optic nerve. We developed an adherent drug-encapsulated bi-layered depot (DBP) as a dual drug vehicle for local treatment to protect the residual retinal ganglion cells (RGCs) and regenerate axons following optic nerve damage. The inner layer of the depot was prepared by co-electrospinning poly(d, l -lactide- co -glycolide acid) (PLGA: 75 : 25) and collagen (COL) with the hydrophobic corticosteroid triamcinolone acetonide (TA) loaded. The outer layer was made of PLGA and the hydrophilic neuroprotective agent Fasudil (FA). The DBP showed suitable morphology, hydrophilicity and mechanical properties, and slowly released TA and FA in vitro by undergoing time-dependent degradation and swelling. All depots showed good biocompatibility with L929 mouse fibroblasts, and DBP was helpful in maintaining the morphology of RGCs in vitro . In addition, direct implantation of DBP at the injured optic nerve in a rat model mitigated inflammation and the death of RGCs, and increased the expression of nerve growth-related protein GAP-43. Therefore, DBP maybe a promising local therapy against TON in future.